Last reviewed · How we verify
CAP-1002
CAP-1002 is an allogeneic cardiosphere-derived cell therapy that promotes cardiac repair and regeneration through paracrine signaling and immunomodulation.
CAP-1002 is an allogeneic cardiosphere-derived cell therapy that promotes cardiac repair and regeneration through paracrine signaling and immunomodulation. Used for Duchenne muscular dystrophy (DMD) with cardiac involvement, Acute myocarditis.
At a glance
| Generic name | CAP-1002 |
|---|---|
| Also known as | Cardiosphere-Derived Cells, CDCs, deramiocel, Allogeneic Cardiosphere-Derived Cells |
| Sponsor | Capricor Inc. |
| Drug class | Allogeneic cell therapy |
| Modality | Biologic |
| Therapeutic area | Cardiovascular |
| Phase | Phase 2 |
Mechanism of action
CAP-1002 consists of cultured cardiosphere-derived cells (CDCs) derived from donor heart tissue that secrete cardioprotective factors and anti-inflammatory cytokines. These cells promote angiogenesis, reduce fibrosis, and modulate the immune response to support recovery of damaged myocardium. The therapy works through paracrine mechanisms rather than direct cell engraftment or differentiation.
Approved indications
- Duchenne muscular dystrophy (DMD) with cardiac involvement
- Acute myocarditis
Common side effects
- Infusion-related reactions
- Pericardial effusion
- Cardiac arrhythmias
Key clinical trials
- A Study of Deramiocel (CAP-1002) in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (PHASE3)
- Open-label Extension of the HOPE-2 Trial (PHASE2)
- A Study of CAP-1002 in Ambulatory and Non-Ambulatory Patients With Duchenne Muscular Dystrophy (PHASE2)
- Intravenous Infusion of CAP-1002 in Patients With COVID-19 (PHASE2)
- HOPE-Duchenne (Halt cardiomyOPathy progrEssion in Duchenne) (PHASE2)
- Regression of Fibrosis & Reversal of Diastolic Dysfunction in HFpEF Patients Treated With Allogeneic CDCs (PHASE2)
- Halt cardiomyOPathy progrEssion in Duchenne (HOPE-OLE) (PHASE2)
- Allogeneic Heart Stem Cells to Achieve Myocardial Regeneration (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- CAP-1002 CI brief — competitive landscape report
- CAP-1002 updates RSS · CI watch RSS
- Capricor Inc. portfolio CI